Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Very high Lp(a) also correlated with higher risks of ischemic stroke and cardiovascular mortality in the Women’s Health Study ...

LP has been promised all the right things by all the right people. Her voice, a glorious warble that spans three octaves, has incited bidding wars between major labels. She’s been signed as an artist ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Elevated lipoprotein(a) increases the risk of major adverse cardiovascular events in patients with and without preexisting atherosclerotic cardiovascular disease (ASCVD), a new study shows. The ...

For many, a 12-inch platter of vinyl, spinning 33 1/3 revolutions per minute, exemplifies how they first listened to music. But long before rock and roll, soul, and other popular music styles were ...